PharmaCann
PrivateLast Round
Series D
Mar 27, 2024
Est. Valuation
$1.05B
Total Funding Raised
$157.69M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
PharmaCann operates in Consumer & Commerce and is based in Chicago, Illinois. Its latest recorded funding round was a Series D round in March 2024.
PharmaCann is a cannabis company that cultivates, processes, and dispenses high-quality medicinal cannabis products while developing innovative cannabinoid-based treatments to enhance the well-being of both adult and pediatric patients.
Sector
Consumer & Commerce
Verticals
D2C Brands, Retail Technology
Business Model
B2C
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PharmaCann Comparables
Compare PharmaCann with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AWH | 93% | |
| Parallel | 89% | |
| Acreage Holdings Inc | 88% |
For institutional investors. Book with your work email.
PharmaCann Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Mar 27, 2024 | ||||
| Series C | Apr 5, 2023 | ||||
| Debt | Jan 20, 2022 | ||||
| Debt | Jun 25, 2021 | ||||
| VC Round | Oct 16, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 72% MoM.
- Apr 17, 2026
Operates in eight states across the US.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- sells_assets_toSep 3, 2026
PharmaCann, Inc. completes the sale of nine operating medical marijuana dispensaries in Pennsylvania to Cresco Labs, LLC for $50M on Sep 2nd '26.
- sells_assets_toAug 25, 2026
On Aug 21st '26, PharmaCann, Inc. plans to sell its New York license and assets—including the Hamptonburgh cultivation and manufacturing facility and four Verilife dispensaries—to Grown Rogue International for an anticipated $4.5M, with definitive agreements expected within four weeks and closing subject to regulatory approval and customary conditions.
- receives_financingAug 21, 2026
On Aug 21st '26, PharmaCann, Inc. receives up to $9M through a secured loan for its New York operation to restart Hamptonburgh production, replenish retail inventory and meet working capital requirements.
For institutional investors. Book with your work email.
PharmaCann Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PharmaCann's valuation, stock price, and market status.
Is PharmaCann a public or private company?
PharmaCann is a private company.
What is the current stock price of PharmaCann?
PharmaCann is a private company, so its shares have no public market price. Caplight tracks PharmaCann's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PharmaCann worth (valuation)?
PharmaCann's valuation is estimated at $1.1B based on funding round data.
Can I buy PharmaCann stock?
PharmaCann shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PharmaCann's last funding round?
PharmaCann's most recent funding round was Series D on March 27, 2024.
Who are the main investors in PharmaCann?
Investor information for PharmaCann is not publicly disclosed.
Will PharmaCann IPO soon?
No public IPO plans have been announced for PharmaCann.
How can I track PharmaCann secondary market activity?
Caplight tracks bids, offers, and trades in PharmaCann's shares on secondary markets.